# AI3 Bio, Inc.: Form D capital raise (Watertown, MA)

**Vendor Spend Propensity Score (CPA / Tax / Audit):** 83/100
**Estimated post-raise budget for this service type:** $966,790 (heuristic)

| Field | Value |
|---|---|
| Industry | Biotechnology (Healthcare & Life Sciences) |
| Operating company | Yes |
| Exemption | 506(b) |
| Amount sold | $48,339,490 |
| Total offering | $48,339,490 |
| Investors so far | 8 |
| First sale | 2026-06-09 |
| Filed | 2026-11-04 |
| Entity | Corporation |

## Executives and related persons (as listed in the filing)
- Steven Altschuler: Executive Officer, Director
- Michael Lyman: Executive Officer
- Nick Seaver: Executive Officer, Director
- Fabian Tenenbaum: Director
- Jeanne Cunicelli: Director
- Alan Ezekowitz: Director
- Jonathan Kagan: Executive Officer

## Why this score
- Operating company: new capital typically funds hiring, facilities and vendors.
- Raised $48,339,490 so far: a large raise.
- Healthcare & Life Sciences companies are a strong fit for CPA / Tax / Audit services.
- New filing (not an amendment): the raise is fresh.
- Filed 2 days ago.

Source: SEC EDGAR Form D filings (U.S. Securities and Exchange Commission) (https://www.sec.gov/Archives/edgar/data/2019875/000201987526000003/). Last refreshed: 2026-11-05T08:45:31.561Z.
Informational only. SEC EDGAR Form D data is shown for business-development research; it is not investment advice and not an offer or solicitation to buy or sell any security. Not legal or financial advice.